Shaw 1986.

Study characteristics
Methods	Trial design: Randomised study
Participants	Participants: 20 women were randomised; 19 analysed  Mean age: 30.4 +/‐ 3.8  Inclusion criteria:  Laparoscopically diagnosed disease  No treatment within 4 months prior to study  Exclusion criteria: not stated  Setting: UK  Timing: not stated
Interventions	Buserelin 200 mcg three times a day intranasally for 6 months (n = 10)  versus  Buserelin 300 mcg three times a day intranasally for 6 months (n = 10)
Outcomes	Symptomatic changes  rAFS score  Adverse effects
Notes	Intention‐to‐treat analysis: No  Sample size calculation: not stated  Funding: Hoechst UK supplied the Buserelin used in this study. No further details provided Note previous version: Authors contacted but unable to provide further details as trial was almost 20 years old
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"randomly allocated". No further details of method used to generate random sequence
Allocation concealment (selection bias)	Unclear risk	No details provided of method used to conceal allocation to treatment groups
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	"this paper reports an open study" with no further details.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	"this paper reports an open study" with no further details.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Detail for attrition: 1 from buserelin 300 mcg TDS group withdrew after 3 months due to adverse effects.
Selective reporting (reporting bias)	High risk	No comparisons between groups for symptomatic changes
Other bias	Low risk	No other risk of bias reported